About the company
Unity Biotechnology Inc. is a pioneering biotechnology company at the forefront of the fight against aging-related diseases. Through innovative research and advanced technologies, the company is dedicated to designing therapeutics that not only prevent the onset of age-related illnesses but also halt and reverse their progress. One of Unity Biotechnology's primary focuses lies in the clearance of senescent cells, which are cells that have entered a state of irreversible growth arrest and accumulate in various tissues as we age. These cells, despite being alive, no longer function properly and secrete harmful molecules that contribute to chronic inflammation, tissue degeneration, and the development of aging-related diseases. By developing senolytic medicines, Unity aims to selectively eliminate these senescent cells from the body, thereby preventing or reversing the detrimental effects they can cause. The uniqueness of Unity's approach lies in targeting vulnerabilities specific to senescent cells while leaving healthy cells unaffected. This targeted approach ensures the preservation of normal cell function, minimizing any potential side effects. By selectively clearing senescent cells, Unity Biotechnology seeks to restore tissue homeostasis and effectively combat age-associated diseases. Among the age-related conditions that Unity focuses on, osteoarthritis is a significant area of interest. Osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage and chronic inflammation, resulting in pain, stiffness, and reduced mobility. By addressing the underlying cause of osteoarthritis—the accumulation of senescent cells—Unity aims to develop therapies that slow down or even reverse the progression of this debilitating condition, providing relief and improving the quality of life for millions of individuals. In addition to osteoarthritis, Unity Biotechnology also directs its efforts toward tackling eye diseases associated with aging. Age-related macular degeneration (AMD), for instance, is a leading cause of vision loss in older adults. By focusing on the clearance of senescent cells in the eye, Unity aims to develop therapies that can prevent or slow down the progression of AMD, preserving vision and preventing further deterioration. Pulmonary diseases, including chronic obstructive pulmonary disease (COPD), are another area where Unity Biotechnology seeks to make a significant impact. COPD is a progressive lung condition characterized by persistent airflow limitation and chronic inflammation, resulting in shortness of breath and reduced lung function. By targeting senescent cells in the lungs, Unity aims to develop therapies that halt the progression of COPD, alleviate symptoms, and improve the overall respiratory function in affected individuals. Unity Biotechnology is driven by a vision to redefine the possibilities of aging and transform the lives of individuals affected by age-related diseases. Through their dedicated research and innovative therapeutic approaches, they are poised to revolutionize the field of biomedicine and bring about a new era of improved health and longevity.
Website: https://unitybiotechnology.com
Data updated: June 2, 2026
